-
Article
Open AccessUnderlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial
It is unclear whether neurotoxicity due to the antiretroviral drug efavirenz (EFV) results in neurocognitive impairment in people living with HIV (PLWH). Previously, we found that discontinuing EFV was associa...
-
Article
Open AccessEstimating regional prevalence of chronic hepatitis C with a capture-recapture analysis
The hepatitis C virus (HCV) infection is a candidate disease for micro-elimination. Accurate baseline HCV prevalence estimation is essential to monitor progress to micro-elimination but can be methodologically...
-
Article
Open AccessHigh efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients
The aim of this study is to assess the effect of efavirenz exposure on neurocognitive functioning and investigate plasma neurofilament light (Nfl) as a biomarker for neurocognitive damage. Sub-analysis of the ...
-
Article
Open AccessIntroducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study
People who inject drugs (PWID) are disproportionally affected by the hepatitis C virus (HCV) infection. In the Netherlands, active HCV transmission in PWID has practically been halted but uptake of HCV testing...
-
Article
Open AccessA Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?
The burden of liver-related morbidity remains high among HIV-infected patients, despite advances in the treatment of HIV and viral hepatitis. Especially, the impact of non-alcoholic fatty liver disease (NAFLD)...
-
Chapter
Correction to: Acute Hepatitis C
The original version of Chapter 4 was inadvertently published with the incorrect Figure 4.1. The correct figure 4.1 has been corrected below:
-
Chapter
Acute Hepatitis C
Acute hepatitis C virus (HCV) infections remain one of the main causes of liver disease worldwide with a varying incidence among different countries. Acute HCV infection classically refers to the first 6 month...
-
Chapter
Acute Hepatitis C
Acute hepatitis C virus (HCV) infections remain one of the main causes of liver disease worldwide with a varying incidence among different countries. Acute HCV infection classically refers to the first 6 month...
-
Article
Open AccessHIV, HCV and HBV: A Review of Parallels and Differences
Elimination of the three blood-borne viruses—human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV)—as public health issues may be plausible in the near future. Spectacular advances have b...
-
Article
Open AccessThe Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study
Pegylated interferon-based therapy for hepatitis C virus (HCV) negatively impacts nutritional state and patient-reported outcomes (PROs) such as health-related quality of life (HRQL). Clinical trials with dire...
-
Article
Open AccessHBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa
Co-infection with HIV negatively impacts the progression of chronic hepatitis B virus (HBV) infection, including causing rapid progression to liver fibrosis. Sub-Saharan Africa represents arguably the most imp...
-
Article
Open AccessNew Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review
Although current therapies can be successful at suppressing hepatitis B viral load, long-term viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with nucleoside/nucleotid...
-
Article
Open AccessPersistent Hepatitis E Infection in a Patient with Tuberous Sclerosis Complex Treated with Everolimus: A Case Report
The incidence of hepatitis E (HEV) genotype 3 is rising in developed countries. HEV infections are usually self-limiting, but can become chronic in immunocompromised patients. This might lead to rapid fibrosis...
-
Article
Open AccessMaraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study
The increased risk of abacavir in cardiovascular disease (CVD) in HIV-infected patients is still being debated. Maraviroc, a CCR5 blocker, has been shown to decrease immune activation and monocyte infiltration...
-
Article
Open AccessPharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
Hepatitis C virus (HCV)-infected patients often suffer from liver cirrhosis, which can be complicated by renal impairment. Therefore, in this review we describe the treatment possibilities in HCV patients with...
-
Article
Open AccessHigh Frequency of Polymicrobial Infections After Surgical Resection of Malignant Bone and Soft Tissue Tumors: A Retrospective Cohort Study
Surgical resection of a malignant bone tumor (BT) or soft tissue tumor (STT), with or without prosthetic replacement, carries a high risk of develo** postoperative infections. There is limited knowledge on t...
-
Article
Open AccessTenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal st...
-
Article
CD4/CD8 ratio is a promising candidate for non-invasive measurement of liver fibrosis in chronic HCV-monoinfected patients
The extent of liver fibrosis is an important factor in prognosis and clinical decision-making in chronic hepatitis C virus (HCV) infection. We investigated CD4/CD8 ratio in HCV-monoinfected and HIV/HCV-coinfec...
-
Article
Activation of extrinsic apoptosis pathway in HCV monoinfected and HIV–HCV coinfected patients, irrespective of liver disease severity
Chronic hepatitis C virus (HCV) infection is associated with increased levels of peripheral T cell apoptosis. We aimed to study whether T cell apoptosis markers indicate pathways that may contribute to clinica...
-
Article
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations
Chronic hepatitis C is a global health problem. To prevent or reduce complications, the hepatitis C virus (HCV) infection needs to be eradicated. There have been several developments in treating these patients...
